Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An update from Urogen Pharma (URGN) is now available.
UroGen Pharma Ltd. has shared promising results from its Phase 3 ENVISION trial for UGN-102, a potential treatment for low-grade non-muscle invasive bladder cancer. The trial met its primary endpoint, showing a high rate of complete response at three months, with many patients maintaining the response at 12 months. The company is progressing with a New Drug Application to the FDA, eyeing a potential market opportunity exceeding $5 billion for UGN-102. If approved, the treatment could offer a significant alternative to the current standard procedure, potentially improving patient outcomes and quality of life.
For a thorough assessment of URGN stock, go to TipRanks’ Stock Analysis page.